Blog english

Bionaturis signs a convertible loan with BTC diez investment fund

For the official disclosing Click here (only in Spanish)

https://www.bolsasymercados.es/mab/documentos/HechosRelev/2017/08/84980_HRelev_20170802.pdf

August Newsletter

Let’s read Bionaturis Group latest news

IN THIS ISSUE

Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biotechnology private investment increases

Let’s get to know…

Lucia Beltran Camacho, 22 years old, born in Tarifa (Cadiz). Degree at Biotechnology by Cadiz University.
 

 

 

-When you were a child, what did you want to be as an adult?
I have always loved everything related to music so I wanted to be a music teacher.
-What do you like the most about your job?
Learning and finding out new things every day.
-What are your future challenges?
Carrying on learning and progressing in order to work as a researcher.
-Your favourite dish
Lasagne.
-A place
Any beach.
-A film
‘Amelie’ ,by Jean-Pierre Jeunet.
-A historical figure
Rosalind Franklin.
-A book
‘The Silver Linings Playbook’, by Matthew Quick.
-A song
‘La piedra invisible’, by Izal.
-What do you usually do in your free time?
I like going to the cinema and spending time with my family and friends. If I have enough time, I love travelling and knowing new places.
-You can’t live without…
Chocolate.
-How do you imagine the world in 20 years?
A world where Science is more important than now and people bet on the progresses that it can offer.

Lucia has been doing a Lab Technician internship at Bionaturis since July, 2016.

Biobide takes part in a research about Malaria funded by Melinda
and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the latest two years. The final end is public institutions […]

August 9th, 2016|Blog english|Comments Off|

Biotechnology private investment increases

The biotech sector continues gaining relevance in the Spanish economy, according to the 2015 Asebio Report, recently published. Among the criteria that show this increasing trend, it is worth noting the private R&D investment, that has returned to growth with 3,75% (533.8 million Euros in 2014) after two consecutive years of downturn. This tendency contrasts to the needs of this sector, that requires an increase of the public economic aids for R&D in order to recuperate, at least, the previous levels to 2008.

“The figures of the report confirm that the biotech sector is a cornerstone in the Spanish economy. The growth in the R&D private investment points out that the companies have made a great effort to continue developing and innovating despite the numerous problems. These figures are endorsed internationally by the latest Ernst&Young Report – Beyond Borders- that shows how the global biotech sector reached a record figure of funding until 62,000 million Euros in 2015”, Bionaturis CEO, Victor Infante, has stated.

The invoicing volume is also very relevant considering that it has already reached 10.35% of the Spanish GDP, rubbing shoulders for the first time in the top ranking with other sectors such as Tourism. This indicator has not stopped growing up even during the crisis, period in which, precisely, it has registered a rise of more than 7%. In 2014 the sector overtook the record of 100,000 million Euros of invoicing and created 178,000 jobs (+3%).

The number of biotech companies (high-technology companies completely devoted to the sector, as Bionaturis Group) grew 13.36% in 2014. As in previous reports, the majority of these companies consider that the internationalization is very important for their growth, because of that, the 86% of the companies integrated […]

August 8th, 2016|Blog english|Comments Off|

Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the lastest two years. The final end is public institutions and the industry sharing more open knowledge in order to progress in new joint developments.

The promising results have just been published in a scientific paper and include the toxicity assays in zebrafish performed by Biobide to test the potential toxicity of the candidates to fight malaria. “Our presence in this study shows the versatility and usefulness of the zebrafish as animal model for drug discovery, as well as our expertise in this field. In addition to the obvious scientific value, this collaborative project has also a very relevant social value for Biobide, that is contributing in this way to find solutions for a disease that affected 95 countries worldwide in 2015”, the R&D Management Director at Biobide, Arantza Muriana, has stated.

In the 290 assays made by the different researchers for this study, 130 compounds have shown potential action against malaria which paves the way for a future election of the most suitable ones to develop new drugs. Additionally, some of these compounds have also shown outstanding activity against other disease agents, including bacteria, fungi, other parasites and even human cancer cells. In fact, these positive results have ignited over 30 drug development program devoted to fight different diseases. This initiative has been so satisfying that promoters are already repeating […]

August 2nd, 2016|Blog english|Comments Off|

July Newsletter

If you want to know Bionaturis Group latest news, here you are our July Newsletter

IN THIS ISSUE

Miriam Bastida, ZIP Solutions: “We want to grow and gain international position with Bionaturis Group”

 

Bionaturis debates about the potentiality of the Biotech sector in Andalusia

Let’s get to know…

Nuria Martinez Mas, born in Manresa, PhD at Organic Chemistry and Biochemistry by Ramon Llull University in Barcelona.
 

 

 

-When you were a child, what did you want to be as an adult?
A doctor, but seeing blood, although it is not mine, makes me feel very nervous. Because of that I had to change my calling!
-What do you like the most about your job?
It lets me learn something new every day.
-What are your future challenges?
I would like to know more about patents. It is a very complex field and it is not my proposal becoming an expert but I think that in my current position I need more knowledge because it can influence in the commercial strategy of the company and therefore in the projects we are working on.
-Your favourite dish
I prefer simple dishes. I enjoy a lot with bread, tomato and a good iberian ham.
-A place
The National Park of Aigüestortes, in the Pyrenees.
-A film
‘Life is beautiful’, by Roberto Benigni.
-A historical figure
Marie Curie, a guide for all the women who work in science.
-A book
Anything by Jo Nesbo, a Norwegian writer of crime novels.
-A song
‘Al mar’, by Manel, a catalan band.
-What do you usually do in your free time?
Free time? What is that? With a one-year-old baby, I do not have much! But when it is possible, I like going with my partner to climb 3,000 metre mountains.
-You can’t live without…
The light of the sun, it is vital to have energy and good mood.
-How […]

July 13th, 2016|Blog english|Comments Off|

Miriam Bastida, ZIP Solutions: “We want to grow and gain international position with Bionaturis Group”

Bionaturis Group continues increasing its high-quality products and services offer for human and animal health in its national and international expansion signing collaboration agreements with third relevant parties, creating new subsidiaries in strategic markets and integrating new companies in its structure by M&A transactions. The latest acquisition of Bionaturis Group is Zera Intein Protein Solutions, ZIP Solutions, an international cutting-edge company well known by its industrial solutions for the expression and purification of biological products, one of the highest growing fields in the Health sector. ZIP’s General Manager, Miriam Bastida, stands out the potentialities of the company and its goals in this new stage.

-What is the speciality of ZIP Solutions?

ZIP Solutions is a biotechnological company devoted to develop and commercialise innovative solutions for industrial and pharmaceutical applications. The company has an in-depth knowledge of the requirements of the human and animal health industry, and offers its proprietary solutions, Zera® and Splittera, as differentiating and highly competitive tools to meet their demanding needs. These solutions, having a wide range of applications, are able to produce, for example, biological products that could turn into first in class vaccines and industrial enzymes (in the case of Zera®), also being part of effective cancer treatments as conjugated antibodies (ADCS) or the standardization of diagnosis kits (Splittera). Besides, Splittera offers a solution for an underserved need within the lucrative sector of biodrugs such as its industrial downstream purification. It is worth noting that nowadays biodrugs, with a global market of $165 billion and a double-digit growth rate, are the top runners of the rankings leading, for instance the top sales worldwide –Humira, by Abbvie, with $14 billion annual sales- or the top-five list on oncological products. Its growth continues […]

July 12th, 2016|Blog english|Comments Off|

Bionaturis debates about the potentiality of the Biotech sector in Andalusia

Bionaturis is one of the participating companies in the ‘Sessions of Innovative Public Procurement: a development opportunity and business for the Biotech Sector in Andalusia’, organized by Technological Corporation of Andalusia (CTA, in Spanish) and BioAndalucia Association. Bionaturis CEO and president, Victor Infante, will represent the company in this forum to discuss about ‘The Biotech Sector Abilities in Andalusia’, along with the companies Biomedal and NeuronBio.

The relevance of Biotechnology in Andalusia is remarkable high considering that this autonomous community has been leading the foundation of new biotech companies in Spain for five years, according to Asebio. At the international level, its role is also outstanding because, as Extenda has pointed out, Andalusia is the fifth Spanish community in exporting biotech products with 614 million Euros in 2015. Another sign of its importance is that six Andalusian companies took part in the latest edition of the Bio International Convention, held last June in San Francisco, being Bionaturis among them. (Please, click here for further information about that)

With the main goal of identifying the key issues of this kind of Innovative Public Procurement and analyzing how the autonomous, national and European legal tools could contribute to it, these sessions gathers experts from public institutions, companies and research institutions. These sessions, mainly practical, will be held in Seville on July 5th.

For further information about the conference, please click here

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). Bionaturis Group has four companies (Bionaturis, Biobide, ZIP Solutions and BNT Pacific) and two subsidiaries (Biobide […]

July 4th, 2016|Blog english, congress|Comments Off|

June Newsletter

If you want to know Bionaturis Group latest news, here you are our June Newsletter

IN THIS ISSUE

Bionaturis Group shows its premium solutions for human and animal health to the Bio International Convention 2016

Bionaturis Group growth, in the MedCap Forum

Let’s get to know…

Aintzane Alday, 37 years old, born in San Sebastian. Phd at Biology by The Basque Country University.
 

 

-When you were a child, what did you want to be as an adult?
I have always wanted to be a doctor. Althoug I moved through the typical phases: an electrician, a teacher, a writer…
-What do you like the most about your job?
It makes me feel good about what I do. It makes me be in my element.
-What are your future challenges?
To continue working in Science and doing my best to promote.
-Your favourite dish
I am very keen on nearly every type of fish, but I really love the sea bream and the turbot. And the seafood makes me crazy, I could not forget it.
-A place
Lampai, a little village in Galicia. I have lived very happy moments in my life in this place. I always feel very relaxed there.
-A film
Although the time goes by, I am still in love with ‘The Neverending Story’. I know it by heart.
-A historical figure
A very attractive character for me has always been ‘Juana la Loca’, above all, so curious character that Literature and Cinema has created.
-A book
In this moment of my life in my 30’s, I would choose “Tell me who I am”, by Julia Navarro.
-A song
‘Hope, there’s someone, like’, by Anthony and the Johnsons. It gives me goosebumps.
-What do you usually do in your free time?
First of all, enjoying with my family and, if my little daugthers let me, I like reading, […]

June 14th, 2016|Blog english|Comments Off|

Bionaturis Group shows its premium solutions for human and animal health to the Bio International Convention 2016

The Bio International Convention 2016 once again will be an essential meeting point in the Bionaturis Group schedule. This event, considered the most important in the biotech sector worldwide, will be held on 6-9th of June in San Francisco (California).

Bionaturis Group is present at the Bio Convention 2016 after a year in which it has strengthened its positioning in the US market after the signing of a contract between Biobide and the US National Institute of Environmental Health (NIEHS), one of the most prestigious and demanding health institutions in the world. Biobide, the Bionaturis Group company that are experts in the use of the zebrafish model, also founded a subsidiary in Maryland in the same year.

In addition, Bionaturis will also highlight at the Bio Convention 2016 the new premium solutions in its portfolio which includes six new developments, five of which are for animal health.  These new developments point to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer. The global Animal Health sector represented an annual figure of $100 billion in 2014. In this area, drugs and vaccines reach until $23 billion (USD) with a CAGR of 6% for 2013-2017.

Bionaturis Group delegates in this edition are the chief scientific officer in Bionaturis, Juan J. Infante, the general Manager of Biobide, Andoni Cruz, and the Global Sales Manager in Bionaturis Group, Eli Kehrli. Biobide’s booth is in the Biobosque Region, inside the Spanish Pavillion (Booth 605). The applications of one-to-one meetings with Bionaturis Group delegates can be arranged emailing to eli.kehrli@bionaturis.com.

Consolidation and new contacts

The main goals of Bionaturis Group in this worldwide event are focused on the consolidation and monitoring of current customers and […]

June 6th, 2016|Blog english, congress|Comments Off|

Bionaturis Group growth, in the MedCap Forum

Bionaturis Group takes part one more year in the Small and Medium-Size Companies Forum -MedCap-, on May 31st and June 1st in Madrid.

Bionaturis Group CEO, Victor Infante, is the person in charge of presenting the latest milestones achieved by the company, among with we can highlight the establishment of the subsidiary BNT China Biosciences in China, the signing of a contract with the US National Institute of Environmental Health (NIEHS) and the recent acquisition of the company ZIP Solutions, that has signed a co-development and exclusive license agreement with a leading multinational company for the final development and market of Splittera® technology.

Thanks to these latest operations, Bionaturis Group continues positioning as a reference company in its area, through its four companies and two subsidiaries with presence in Europe, USA and Asia. The Group offers premium services and products for human and animal health.

In this edition of the MedCap Forum, Bionaturis Group takes part in both ‘One to One’ meetings and the Discovery Meeting, with a lecturer in the afternoon on May, 31st, available here.

About the MedCap

The 11nd MEDCAP Forum gathers the main Small and Medium Size Companies listed on the Spanish Stock Exchange Market as well as institutional investors, brokers and financial analysts. The program includes both sectorial and general round tables, as well as the possibility of holding ‘One to One’ meetings. The main goal of the event is to stimulate the liquidity and founding of these companies.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). In addition to this […]

May 31st, 2016|Blog english, congress, Hechos Relevantes|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR